The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring

Overview

Journal Clin Diabetes

Specialty Endocrinology

Date 2020 Nov 2

PMID 33132504

Authors

Pamela R Kushner

Davida F Kruger

Affiliations

Soon will be listed here.

Abstract

Continuous glucose monitoring (CGM) provides comprehensive assessment of daily glucose measurements for patients with diabetes and can reveal high and low blood glucose values that may occur even when a patient's A1C is adequately controlled. Among the measures captured by CGM, the percentage of time in the target glycemic range, or "time in range" (typically 70-180 mg/dL), has emerged as one of the strongest indicators of good glycemic control. This review examines the shift to using CGM to assess glycemic control and guide diabetes treatment decisions, with a focus on time in range as the key metric of glycemic control.

Citing Articles

Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes.

Frias J, Ratzki-Leewing A, Dex T, Meneghini L, Rodrigues A, Shah V Diabetes Obes Metab. 2025; 27(4):2173-2182.

PMID: 39905643 PMC: 11885071. DOI: 10.1111/dom.16214.

References

Rodbard H, Peters A, Slee A, Cao A, Traina S, Alba M . The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes. Diabetes Care. 2016; 40(2):171-180. DOI: 10.2337/dc16-1353. View

Peters A, Ahmann A, Battelino T, Evert A, Hirsch I, Murad M . Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101(11):3922-3937. DOI: 10.1210/jc.2016-2534. View

Frias J, Nakhle S, Ruggles J, Zhuplatov S, Klein E, Zhou R . Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2016; 19(1):40-48. PMC: 6168745. DOI: 10.1111/dom.12763. View

Kohnert K, Heinke P, Vogt L, Salzsieder E . Utility of different glycemic control metrics for optimizing management of diabetes. World J Diabetes. 2015; 6(1):17-29. PMC: 4317309. DOI: 10.4239/wjd.v6.i1.17. View

Zaharieva D, Turksoy K, McGaugh S, Pooni R, Vienneau T, Ly T . Lag Time Remains with Newer Real-Time Continuous Glucose Monitoring Technology During Aerobic Exercise in Adults Living with Type 1 Diabetes. Diabetes Technol Ther. 2019; 21(6):313-321. PMC: 6551983. DOI: 10.1089/dia.2018.0364. View

van Bloemendaal L, Ten Kulve J, la Fleur S, IJzerman R, Diamant M . Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2013; 221(1):T1-16. DOI: 10.1530/JOE-13-0414. View

Davies M, DAlessio D, Fradkin J, Kernan W, Mathieu C, Mingrone G . Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018; 61(12):2461-2498. DOI: 10.1007/s00125-018-4729-5. View

Martin-Timon I, Del Canizo-Gomez F . Mechanisms of hypoglycemia unawareness and implications in diabetic patients. World J Diabetes. 2015; 6(7):912-26. PMC: 4499525. DOI: 10.4239/wjd.v6.i7.912. View

Battelino T, Danne T, Bergenstal R, Amiel S, Beck R, Biester T . Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019; 42(8):1593-1603. PMC: 6973648. DOI: 10.2337/dci19-0028. View

10.

Shaefer Jr C, Kushner P, Aguilar R . User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015; 127(8):818-26. DOI: 10.1080/00325481.2015.1090295. View

11.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

12.

Vigersky R, Fonda S, Chellappa M, Walker M, Ehrhardt N . Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care. 2011; 35(1):32-8. PMC: 3241321. DOI: 10.2337/dc11-1438. View

13.

Lucidi P, Porcellati F, Bolli G, Fanelli C . Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology. Curr Diab Rep. 2018; 18(10):83. DOI: 10.1007/s11892-018-1065-6. View

14.

Carlson A, Mullen D, Mazze R, Strock E, Richter S, Bergenstal R . EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSIS. Endocr Pract. 2019; 25(4):306-314. DOI: 10.4158/EP-2018-0177. View

15.

Bergenstal R, Gal R, Connor C, Gubitosi-Klug R, Kruger D, Olson B . Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels. Ann Intern Med. 2017; 167(2):95-102. DOI: 10.7326/M16-2596. View

16.

Aleppo G, Laffel L, Ahmann A, Hirsch I, Kruger D, Peters A . A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System for the Management of Adults With Diabetes. J Endocr Soc. 2018; 1(12):1445-1460. PMC: 5760210. DOI: 10.1210/js.2017-00388. View

17.

Lipska K, Warton E, Huang E, Moffet H, Inzucchi S, Krumholz H . HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care. 2013; 36(11):3535-42. PMC: 3816866. DOI: 10.2337/dc13-0610. View

18.

. 6. Glycemic Targets: . Diabetes Care. 2018; 42(Suppl 1):S61-S70. DOI: 10.2337/dc19-S006. View

19.

Beck R, Bergenstal R, Riddlesworth T, Kollman C, Li Z, Brown A . Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2018; 42(3):400-405. PMC: 6905478. DOI: 10.2337/dc18-1444. View

20.

Kovatchev B . Metrics for glycaemic control - from HbA to continuous glucose monitoring. Nat Rev Endocrinol. 2017; 13(7):425-436. DOI: 10.1038/nrendo.2017.3. View